Security key
09075P105
BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 (BTAI)
CUSIP: 09075P105
Q1 2019 13F Holders as of 31 Mar 2019
- Type / Class
- Equity / Common Stock, par value $0.001
- Shares outstanding
- 27,093,277
- Total 13F shares
- 2,512,687
- Share change
- +91,970
- Total reported value
- $24,935,000
- Price per share
- $9.89
- Number of holders
- 19
- Value change
- +$931,694
- Number of buys
- 14
- Number of sells
- 6
Report period
Q1 2019
Institutions
19
Top holders
10
BTAI full security history
Newer quarter: Q2 2019
Previous quarter: Q4 2018
BioXcel Therapeutics, Inc. SEC filings
BioXcel Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 09075P105
Recent filing periods:
Top shareholders of BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Artemis Investment Management LLP |
13F
|
Company |
4.3%
|
1,163,013
|
$4,501,000 | — | 31 Dec 2018 | |
| FMR LLC |
13F
|
Company |
3.2%
|
861,135
|
$3,324,000 | — | 31 Dec 2018 | |
| CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM |
13F
|
Company |
1.1%
|
298,400
|
$1,152,000 | — | 31 Dec 2018 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.22%
|
58,257
|
$224,000 | — | 31 Dec 2018 | |
| BlackRock Finance, Inc. |
13F
|
Company |
0.06%
|
15,307
|
$59,000 | — | 31 Dec 2018 | |
| UBS Group AG |
13F
|
Company |
0.05%
|
12,721
|
$49,000 | — | 31 Dec 2018 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.02%
|
5,146
|
$19,000 | — | 31 Dec 2018 | |
| MORGAN STANLEY |
13F
|
Company |
0.02%
|
4,100
|
$16,000 | — | 31 Dec 2018 | |
| BANK OF MONTREAL /CAN/ |
13F
|
Company |
0%
|
1,216
|
$5,000 | — | 31 Dec 2018 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0%
|
1,122
|
$4,000 | — | 31 Dec 2018 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
300
|
$1,000 | — | 31 Dec 2018 |
Institutional Holders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 (BTAI) as of Q1 2019
As of 31 Mar 2019,
BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 (BTAI) was held by
19 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
2,512,687 shares.
The largest 10 holders included
Artemis Investment Management LLP, FMR LLC, CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM, VANGUARD GROUP INC, UBS Group AG, RENAISSANCE TECHNOLOGIES LLC, Creative Planning, GEODE CAPITAL MANAGEMENT, LLC, BlackRock Inc., and MILLENNIUM MANAGEMENT LLC.
This page lists
19
institutional shareholders reporting positions in this security
for the Q1 2019 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2019 vs Q4 2018 Across Filers
Q4 2018 holders
11
Q1 2019 holders
19
Holder diff
8
| Investor | Q4 2018 Shares | Q1 2019 Shares | Share Diff | Share Chg % | Q4 2018 Value $ | Q1 2019 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.